Commercial Performance - RYTELO Q2 2025 sales reached $49 million[12] - There was an approximate 17% demand increase for RYTELO in Q2 2025 compared to Q1 2025[14] - Approximately 30% of new RYTELO patients starts are in the 1st and 2nd line of treatment[14] - RYTELO has secured favorable coverage policies for approximately 90% of covered lives[14] - Since approval, approximately 400 new ordering accounts have been added year-to-date[14] Clinical Development - The Phase 3 IMpactMF trial is expected to be 100% enrolled by the end of 2025[11, 22] - An interim analysis of the IMpactMF trial is expected in the second half of 2026, with the final analysis anticipated in the second half of 2028[22] Financial Status - The company's cash and marketable securities totaled $432.6 million as of June 30, 2025[25] - Q2 2025 total operating expenses were $61.5 million[25] - The company anticipates operating expenses in the range of $270 million to $285 million for 2025[25]